Oncology · Small MoleculePipeline Updatecompetitivemid-term

Apotex submits supplemental ANDA for Pomalidomide

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/7/2026, 6:32:07 PM

Assessment confidence: 62% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The submission of a supplemental ANDA for Pomalidomide by Apotex signifies a potential increase in market competition, which could lead to pricing pressures and shifts in market share. Pharma strategy teams must evaluate how this development may affect their product positioning and sales forecasts. Regulatory context from FDA (FDA AP — POMALIDOMIDE (SUPPL)) supports the near-term read. Assessment grounded in 27 ranked evidence items (9 high-relevance).

Strategic Assessment

Portfolio and strategy teams should assess the potential impact of increased competition on sales forecasts and market positioning. The strongest clinical anchor is Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With PD-L1 Expression < 1% or (ClinicalTrials.gov), sponsor/company relevance (novartis). In Oncology · Small Molecule, 8 regulatory and 4 competitive items passed relevance filtering for Apotex.

Competitive Pressure

The most relevant competitive pressure comes from Lupin's Lenalidomide ANDA214398 Receives Abbreviated Approval (Humanexa Signals) — moderate corpus alignment. Secondary pressure from Sandoz Receives FDA Approval for Enzalutamide ANDA216068. This submission may increase competition in the market for Pomalidomide, potentially impacting pricing and market share for existing products.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — POMALIDOMIDE (SUPPL) (FDA). Entity match (apotex); Regulatory pathway relevance (nda). The submission is part of the standard regulatory process and does not indicate immediate changes to approval or compliance requirements.

Key Opportunities

Increased competition may lead to reduced prices and impact revenue for existing Pomalidomide products, affecting overall market dynamics.
Homeopathic products are marketed without FDA review and may not meet modern standards for safety, effectiveness, quality and labeling. Learn more.
Lead sponsor: Janssen Research & Development, LLC.
Portfolio and strategy teams should assess the potential impact of increased competition on sales forecasts and market positioning.

What Would Change This Assessment

This becomes more urgent if Monitor the FDA's review timeline and any subsequent approvals or market entries by Apotex.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — POMALIDOMIDE (SUPPL)
FDAhigh relevance
Entity match (apotex); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — POMALIDOMIDE (SUPPL)
FDAhigh relevance
Entity match (pomalidomide); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — POMALIDOMIDE (SUPPL)
FDAhigh relevance
Entity match (pomalidomide); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — POMALIDOMIDE (SUPPL)
FDAhigh relevance
Entity match (pomalidomide); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — POMALIDOMIDE (SUPPL)
FDAhigh relevance
Entity match (pomalidomide); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — IMIQUIMOD (SUPPL)
FDAhigh relevance
Entity match (apotex); Regulatory pathway relevance (nda)
FDA document
View source
Some Homeopathic Products May Put You at Risk
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
Data Standards Program Strategic Plan and Board
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With PD-L1 Expression < 1% or
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
Study of Amivantamab, Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Suction Mini-PCNL Versus Standard PCNL for the Management of 2-4cm Kidney Stones
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Robotic Minimally Invasive Inguinal Hernia Repair Post-Market Clinical Study With the DEXTER Robotic System
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Ultrasound-Guided Versus Standard Margin Selection in Ileocecal Resection of Terminal Ileal CD
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Lupin's Lenalidomide ANDA214398 Receives Abbreviated Approval
Humanexa Signalsmedium relevance
Moderate corpus alignment
Sandoz Receives FDA Approval for Enzalutamide ANDA216068
Humanexa Signalsmedium relevance
Moderate corpus alignment
Novel bispecific T-cell engagers show promise against EGFR resistance in cancer
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Approval for Thalidomide ANDA213267 by NATCO
Humanexa Signalsmedium relevance
Moderate corpus alignment

Inflammation and carcinogenesis: molecular targets and small-molecule intervention strategies.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Colorectal cancer care in Uganda: a narrative review and case-based health needs assessment from Mbarara Regional Referral Hospital.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
In vitro screening of compounds for targeting gastric cancer with Y220C p53 mutation: a molecule combining zinc chelation and Michael acceptor drives CDKN1 and BBC3 expression to restore a p53-depende
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of caffeine gum on same-day and subsequent neuromuscular performance under a standardized resistance-priming condition in male basketball players.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Inhibition of STAT3-mediated glycolysis by bruceine D suppresses non-small-cell lung cancer progression in vitro and in vivo.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Type 2 diabetes remission in gynaecologic oncology patients completing an acute preoperative weight loss protocol: a case series.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Apotex
Pomalidomide
existing market competitors

Commercial impact

medium

Increased competition may lead to reduced prices and impact revenue for existing Pomalidomide products, affecting overall market dynamics.

Regulatory impact

low

The submission is part of the standard regulatory process and does not indicate immediate changes to approval or compliance requirements.

What to watch

Monitor the FDA's review timeline and any subsequent approvals or market entries by Apotex.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.